Concordia Healthcare Corp. (NASDAQ:CXRX)’s share price rose 4.3% during trading on Tuesday . The company traded as high as $18.76 and last traded at $18.57, with a volume of 285,766 shares. The stock had previously closed at $17.80.

CXRX has been the topic of a number of recent analyst reports. Zacks Investment Research upgraded Concordia Healthcare Corp. from a “hold” rating to a “buy” rating and set a $23.00 price objective on the stock in a research note on Wednesday, July 13th. Laurentian Bank of Canada dropped their price objective on Concordia Healthcare Corp. from $60.00 to $55.00 and set a “buy” rating on the stock in a research note on Monday, March 28th. CIBC lifted their price objective on Concordia Healthcare Corp. from $31.00 to $34.00 and gave the stock a “sector performer” rating in a research note on Tuesday, March 29th. Laurentian restated a “buy” rating and set a $55.00 price target (down from $60.00) on shares of Concordia Healthcare Corp. in a research note on Thursday, March 31st. Finally, Royal Bank Of Canada restated an “outperform” rating and set a $73.50 price target (down from $81.00) on shares of Concordia Healthcare Corp. in a research note on Saturday, April 23rd. Four investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $48.88.

The firm’s 50 day moving average price is $21.58 and its 200-day moving average price is $26.73. The company’s market cap is $937.16 million.

Concordia Healthcare Corp. (NASDAQ:CXRX) last posted its quarterly earnings data on Friday, May 13th. The company reported $1.35 EPS for the quarter, missing the Zacks’ consensus estimate of $1.54 by $0.19. The firm had revenue of $228.50 million for the quarter, compared to the consensus estimate of $231 million. Concordia Healthcare Corp.’s quarterly revenue was up 570.1% compared to the same quarter last year. On average, analysts predict that Concordia Healthcare Corp. will post $6.15 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Friday, July 29th. Investors of record on Friday, July 15th will be paid a $0.075 dividend. The ex-dividend date of this dividend is Wednesday, July 13th. This represents a $0.30 annualized dividend and a yield of 1.63%.

A number of large investors have recently modified their holdings of CXRX. Diamond Hill Capital Management Inc. increased its stake in shares of Concordia Healthcare Corp. by 294.2% in the fourth quarter. Diamond Hill Capital Management Inc. now owns 850,645 shares of the company’s stock valued at $34,732,000 after buying an additional 634,880 shares during the period. Morgan Stanley increased its stake in shares of Concordia Healthcare Corp. by 24.6% in the fourth quarter. Morgan Stanley now owns 269,768 shares of the company’s stock valued at $11,015,000 after buying an additional 53,305 shares during the period. Thornburg Investment Management Inc. increased its stake in shares of Concordia Healthcare Corp. by 48.3% in the fourth quarter. Thornburg Investment Management Inc. now owns 116,235 shares of the company’s stock valued at $4,746,000 after buying an additional 37,847 shares during the period. GSA Capital Partners LLP purchased a new stake in shares of Concordia Healthcare Corp. during the fourth quarter valued at about $2,419,000. Finally, ProShare Advisors LLC purchased a new stake in shares of Concordia Healthcare Corp. during the fourth quarter valued at about $1,671,000.

Concordia Healthcare Corp. is a Canada-based diverse healthcare company. The Company is focused on legacy pharmaceutical products and orphan drugs. The Company operates through three segments, which includes Legacy Pharmaceutical Division, Concordia Pharmaceuticals Inc, which consists of 23 products, including Nilandron, for the treatment of metastatic prostate cancer; Dibenzyline, for the treatment of pheochromocytoma; Lanoxin, for the treatment of mild-to-moderate heart failure and atrial fibrillation; Plaquenil, for the treatment of lupus and rheumatoid arthritis; Donnatal, for the treatment of irritable bowel syndrome, and Zonegran (zonisamide), for treatment of partial seizures in adults with epilepsy.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.